DelSiTech is an innovative drug delivery and development technology company that works with its pharma and biotech partners to turn their active agents into novel and commercially viable therapeutic drug products. In addition, DelSiTech develops its own supergeneric/505(b)(2) products based on its proprietary drug delivery Silica matrix. With this platform, it is possible to develop controlled/sustained release products more precisely, safely and effectively. DelSiTech's first in-house drug product is DST1308 Injection Depot which addresses significant unmet medical needs in chronic hepatitis B infection. DelSiTech´s first topical ophthalmic product DST2105 represents the first-in-class long-acting artificial tear treatment for relieving dry eye symptoms and has entered phase1 clinical trial in March 2023.